Related Experiment Video

Updated: Jul 27, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.8K

Defining the pediatric response to SARS-CoV-2 variants

Reanne M Ho1,2,3, Asha C Bowen2,3,4,5, Christopher C Blyth2,3,4

  • 1Wal-yan Respiratory Research Centre, Telethon Kids Institute, University of Western Australia, Nedlands, WA, Australia.

Frontiers in Immunology
|June 12, 2023
PubMed

Insights

Children experienced milder COVID-19 initially, but future variants may pose risks. Understanding differing immune responses and inflammatory markers is crucial for protecting vulnerable children from severe coronavirus disease 2019 (COVID-19).

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Immunology

Background:

  • The COVID-19 pandemic disproportionately affected older adults, leading to underprioritization of pediatric research.
  • Children generally exhibited less severe responses to SARS-CoV-2 infection compared to adults.

Purpose of the Study:

  • To explore factors behind the milder COVID-19 course in children.
  • To assess risks posed by emerging SARS-CoV-2 variants to pediatric populations.
  • To identify critical research gaps for protecting children.

Main Methods:

  • Review of existing literature on pediatric COVID-19.
  • Analysis of factors influencing viral entry and immune response in children.
  • Examination of inflammatory markers differentiating critical and non-critical cases.

Main Results:

  • Differences in viral entry receptor expression and immune responses contribute to milder pediatric COVID-19.
  • Future variants may increase severe disease risk in children, especially those with comorbidities.
  • Distinct inflammatory profiles exist between critical and non-critical pediatric COVID-19 cases.

Conclusions:

  • While children have been less severely impacted by COVID-19, vigilance is needed.
  • Emerging variants and comorbidities necessitate further research into pediatric SARS-CoV-2 pathogenesis.
  • Targeted research is essential to safeguard vulnerable children from severe COVID-19 outcomes.

Keywords:
COVID-19SARS-CoV-2age-specific responsecellular biologychildrenemerging variantsmolecular biologypediatric

More Related Videos

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.3K
Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic09:03

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic

Published on: November 7, 2020

4.9K

Related Concept Videos

Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
15.3K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
287